The global regenerative medicines market is expected to reach USD 49.41 billion by 2021 from USD 17.06 billion in 2016, at a CAGR of 23.7% during the period of 2016-2021. The high growth in this segment is attributed to the variety of products and technologies and rapid increase in the demand of organ transplantation due to which they are most preferred in various applications.
Based on therapy, the regenerative medicines market is segmented into cell therapy, gene therapy, immunotherapy, and tissue engineering. The cell therapy segment is expected to account for the largest share of the market in 2016. Increasing funding from various governments and private organizations for carrying out research and development activities related to various cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness regarding the benefits of stem cell therapies will drive the growth of this segment.
Growth in the North American segment is primarily driven by rising incidences of cancer, increasing government support, expanding biopharmaceutical industry, and launch of new products in the market.
The major factors contributing to the growth of the regenerative medicines market include rising regulatory approvals for cell culture-based products, increasing funding for cell-based research, and technological advancements. On the other hand, high cost of research and lack of infrastructure, especially in emerging economies, are the major factors restraining the growth of this market.
Acelity (KCI Licensing)
Cytori Therapeutics Inc.
Japan Tissue Engineering Co., Ltd (Subsidiary of Fujifilm Holdings Corporation)
Vertex Pharmaceuticals Incorporated
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Global Regenerative Medicines Market, By Product
7 Global Regenerative Medicines Market, By Therapy